Compare PNC & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNC | SNY |
|---|---|---|
| Founded | 1852 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.8B | 104.5B |
| IPO Year | 2010 | 2001 |
| Metric | PNC | SNY |
|---|---|---|
| Price | $237.02 | $42.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $241.97 | $58.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-15-2026 | 04-23-2026 |
| Dividend Yield | 3.11% | ★ 3.47% |
| EPS Growth | ★ 20.74 | N/A |
| EPS | ★ 8.94 | N/A |
| Revenue | ★ $23,099,000,000.00 | N/A |
| Revenue This Year | $16.53 | $3.49 |
| Revenue Next Year | $4.73 | $6.10 |
| P/E Ratio | $26.93 | ★ $6.14 |
| Revenue Growth | ★ 7.16 | N/A |
| 52 Week Low | $176.88 | $40.89 |
| 52 Week High | $258.96 | $52.68 |
| Indicator | PNC | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 36.28 |
| Support Level | $236.79 | $42.30 |
| Resistance Level | $241.89 | $45.22 |
| Average True Range (ATR) | 4.16 | 0.58 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 39.26 | 0.55 |
PNC Financial is one of the three super-regional banks in the US, with over $600 billion in total assets at the end of March 2026. Headquartered in Pittsburgh, Pennsylvania, PNC Financial has a coast-to-coast branch network, with a strong presence in the US Midwest and Northeast. It closed its acquisition of FirstBank in January 2026, which added around $26 billion in assets to its balance sheet, and PNC is currently expanding in the Southern and Western regions of the US. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, asset management, and investment banking. PNC derived around 38% of revenue from fee income and 62% from net interest income in 2025.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.